Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.104,91
0,34%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vigil Neuroscience Inc (VIGL) Vigil Neuroscience Inc (VIGL) Notizie

Vigil Neuroscience Inc

VIGL
3,03
0,29 (10,58%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
17/4/202422:05GLOBEVigil Presents Key Findings from ILLUMINATE & IGNITE Studies..
26/3/202412:05GLOBEVigil Neuroscience Reports Fourth Quarter and Full Year 2023..
20/3/202412:05GLOBEVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief..
13/3/202412:05GLOBEVigil Announces Upcoming Presentations at 2024 American..
12/3/202412:05GLOBEVigil Neuroscience to Present at Stifel 2024 Virtual CNS..
06/3/202422:25GLOBEVigil Announces Oral Presentation on Small Molecule TREM2..
02/3/202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202423:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:05GLOBEVigil Presents Poster on Impacts of Misdiagnosis and Genetic..
14/2/202417:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:05GLOBEVigil Neuroscience to Present at Guggenheim 6th Annual..
11/1/202416:30EDGAR2Form 8-K - Current report
03/1/202422:30GLOBEVigil Neuroscience Provides 2023 Year-in-Review and..
22/11/202322:05GLOBEVigil Neuroscience to Present at Evercore ISI 6th Annual..
16/11/202322:31EDGAR2Form 8-K - Current report
16/11/202322:05GLOBEVigil Neuroscience Reports Positive Interim Data from Phase..
07/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:15EDGAR2Form 8-K - Current report
07/11/202313:05GLOBEVigil Neuroscience Reports Third Quarter 2023 Financial..
17/10/202313:05GLOBEVigil Neuroscience Announces First Participant Dosed in..
12/10/202322:06EDGAR2Form 8-K - Current report
05/10/202322:01GLOBEVigil Neuroscience to Present at Jefferies Inaugural Biotech..
26/9/202313:05GLOBEVigil Neuroscience Receives Positive Opinion from European..
13/9/202313:31EDGAR2Form 8-K - Current report
11/9/202318:00GLOBEVigil Neuroscience Presents VGL101 Complete Phase 1 Data and..
08/9/202322:10EDGAR2Form 8-K - Current report
08/9/202322:05GLOBEVigil Neuroscience Announces Update on its Small Molecule..
08/9/202313:05GLOBEVigil Neuroscience to Present at 2023 Morgan Stanley Global..
08/8/202313:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:19EDGAR2Form 8-K - Current report
08/8/202313:05GLOBEVigil Neuroscience Reports Second Quarter 2023 Financial..
08/8/202300:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202300:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/8/202322:05GLOBEVigil Neuroscience Appoints Christopher J. Silber, M.D. as..
01/6/202313:00GLOBEVigil Neuroscience to Present at 2023 Jefferies Global..
10/5/202313:00GLOBEVigil Neuroscience Reports First Quarter 2023 Financial..
09/5/202313:00GLOBEVigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D...
08/5/202313:08GLOBEVigil Neuroscience Launches ALSPAware to Provide Access to..
Apertura: 2,72 Min: 2,67 Max: 3,05
Chiusura: 2,74

La tua Cronologia

NASDAQ
VIGL
Vigil Neuroscience
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network